Clinical Study and Literature Analysis of Rhabdomyolysis in Hypothyroidism Caused by Fenofibrate
TANG Yan1a, SONG Qin2, HU Yang1a, DU Bo-ran3, ZHANG Bo1a, ZHU Hui-juan1b, DUAN Lian1b*
1a. Department of Pharmacy, 1b. Department of Endocrinology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730,China; 2. Department of Pharmacy, Beijing Xiaotangshan Hospital, Beijing 102211, China; 3. Department of Pharmacy, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China
Abstract：OBJECTIVE To explore clinical characteristics of rhabdomyolysis caused by fenofibrate in patients with hypothyroidism. METHODS A clinical case was analyzed and summarized the literature of adverse reactions of rhabdomyolysis caused by fenofibrate in patients with hypothyroidism reported in China and abroad. RESULTS A 25-year-old female with hyperlipidemia combined with hypothyroidism developed rhabdomyolysis at 12th day after taking fenofibrate. Before the occurrence of rhabdomyolysis, highlevelof TSH was detected. After occurrence of adverse reactions, the patient stopped taking fenofibrate, rehydrated and alkalized urine. Then the patient recovered and discharged. In the literature review, 11 cases of rhabdomyolysis with fenofibrate in hypothyroidism were included. The age range was 25-68. The sex ratio was 1∶2. On thyroid function, there were 3 cases unknown, 6 cases with hypothyroidism and 2 cases with FT4 at the lowest normal limit. On doses of fenofibrate, there were 9 cases under the instructions, and 3 cases beyond the recommendations in labeling. Most adverse drug reactions (ADRs) occurred at the third to 60th day after taking fenofibrate. Ten patients recovered and 2 patients improved. CONCLUSION Hypothyroidism would be a risk factor for rhabdomyolysis caused by fenofibrate. Thyroid function should be monitored in patients taking fenofibrate with hypothyroidism.
唐彦, 宋钦, 胡扬, 杜博冉, 张波, 朱惠娟, 段炼. 非诺贝特致甲状腺功能减退患者横纹肌溶解[J]. 中国药学杂志, 2020, 55(16): 1372-1375.
TANG Yan, SONG Qin, HU Yang, DU Bo-ran, ZHANG Bo, ZHU Hui-juan, DUAN Lian. Clinical Study and Literature Analysis of Rhabdomyolysis in Hypothyroidism Caused by Fenofibrate. Chinese Pharmaceutical Journal, 2020, 55(16): 1372-1375.
YANG C Y, HE G. Fenofibrate-associated rhabdomyolysis in a hypothyroidism patient: a case. Chin J Drug Appl Monitor(中国药物应用与监测), 2010, 7(6): 383-384.
[2]
FENG X M, XU Y.A case of fenofibrate-related rhabdomyolysisin a patient of anterior pituitary hypofunction. Chin General Pract(中国全科医学), 2010, 13(8): 904-905.
[3]
WANG C, AI D Y. A case of fenofibrate-related rhabdomyolysis. Her Med(医药导报), 2004(2): 126.
[4]
YU H M, JIAO F L. A case of fenofibrate-related rhabdomyolysis. J Hubei Univ Med(湖北医学院学报), 2017, 36(2): 170-171.
[5]
LU Q. Fenofibrate-associated rhabdomyolysis and liver injury. Chin J Pharmacoepidemiol(药物流行病学杂志), 2010, 19(5): 284.
[6]
ZHANG W L. A case of fenofibrate-related rhabdomyolysis. Med J Nat Defend Forces North China(华北国防医药), 2009, 21(5): 33.
[7]
ZHANG J Y, WEI J P. A case of overdose fenofibrate-inducedrhabdomyolysis. J Pract Med(实用医学杂志), 2012, 28(19): 3317.
[8]
ZHANG M, LIU S L, WU N Q, et al. Combination of simvastatin and fenofibrate induced drug-associated myopathyinhypothyroidism patient: a case report. Chin Circul J(中国循环杂志), 2017, 32(9): 849.
[9]
LI D. A case report of fenofibrate-associated acute rhabdomyolysis. Chin J Integr Tradit West Med Intensive Crit Care(中国中西医结合急救杂志), 2013(4): 255. WANG D, WANG Y. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with hypothyroidism: a rare case report and literature review. Medicine (Baltimore), 2018, 97(14): e318-320. SOUSA A A, KRONIT H S, NEVES F A, et al. Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism. Arq Bras Endocrinol Metabol, 2009, 53(3): 383-386. ADKINS J C, FAULDS D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs, 1997, 54(4): 615-633. Joint committee of prophylaxis and treatment of dyslipidemia in Chinese Adults Prophylaxis and treatment Guideline of dyslipidemiain Chinese Adults(2016 revised Edition) . Chin J Health Manage(中华健康管理学杂志), 2017, 11(1): 7-28. HEKIMSOY Z, OKTE M I K. Serum creatine kinase levels in overt and subclinical hypothyroidism. Endocr Res, 2005, 31(3): 171-175.
2020, Vol. 55 
